Pfizer in its $43 billion acquisition of Seagen

On March 13, 2023, Pfizer and Seagen announced that they had entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash, for a total enterprise value of approximately $43 billion.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer.